3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
5
Active not recruiting
2
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Prostatic Neoplasms
6
Carcinoma, Renal Cell
5
Brain Neoplasms
3
Neoplasm Metastasis
2
Multiple Myeloma
2
Melanoma
2
Kidney Neoplasms
2
Glioma
2
Glioblastoma
2
Carcinoma, Transitional Cell
2
Carcinoma, Non-Small-Cell Lung
2
Astrocytoma
2
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Thyroid cancer, medullary
1
Thyroid Neoplasms
1
Thyroid Diseases
1
Thyroid Cancer, Papillary
1
Thrombocytosis
1
Skin Neoplasms
1
Salivary Gland Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Pain
1
Osteosarcoma
1
Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Interventions
Ifosfamide
6
Leucovorin
5
Doxorubicin
4
Dexrazoxane
4
Cisplatin
4
Methotrexate
3
Filgrastim
3
Carboplatin
3
mifamurtide
2
glucarpidase
2
Radiotherapy
2
Neoadjuvant Therapy
2
Mesna
2
Granulocyte-Macrophage Colony-Stimulating Factor
2
Granulocyte Colony-Stimulating Factor
2
Gemcitabine
2
Cryosurgery
2
Chemotherapy, Adjuvant
2
temsirolimus
1
sintilimab
1
sargramostim
1
saracatinib
1
samarium Sm-153 lexidronam
1
robatumumab
1
pembrolizumab
1
pegfilgrastim
1
pazopanib
1
omburtamab I-131
1
niraparib
1
lexatumumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Osteosarcoma
×
cabozantinib
×
Clear all
NCT06341712
2026-03-31
CabOSTar
Ipsen
Phase 2
Terminated
10 enrolled